2025 Q3 -tulosraportti
Vain PDF
90 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
2 892
Myynti
Määrä
8 454
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 343 | - | - | ||
| 766 | - | - | ||
| 27 | - | - | ||
| 30 | - | - | ||
| 460 | - | - |
Ylin
6,64VWAP
Alin
6,42VaihtoMäärä
2,4 372 014
VWAP
Ylin
6,64Alin
6,42VaihtoMäärä
2,4 372 014
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 373 021 | 373 021 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 373 021 | 373 021 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 27.2. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 21.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sittenWhat do you primarily want to see in the report?
2 päivää sitten2 päivää sittenI don't expect anything that wasn't already said at KMD. CU/EAP is the next possible trigger.
·20.2.Take the opportunity to invest more now before the report
·20.2.Super positive on Cereno, but don't think the report will make any big difference. Have more faith in EAP/CU data towards the end of the quarter.·2 päivää sittenI would rather argue that it is strategically wise not to draw focus away from the clinical results by mixing in a financial report where the only thing we know for sure is that the company is losing money... Even if it is completely according to plan... What needed to be said about the financial aspects was said at the Capital Markets Day, I see this report as a non-event. But that's just me... :P
16.2.16.2.Just a sad look for Cereno right now. The people spouting utter nonsense about the 10SEK valuation being justified and holding should be ashamed. It was always going to happen - small cap biotech just happens to live off of hype and news. When there is none and progress is slow, volume dies down and so does appreciation. Insert a couple of big players with exercisable warrants at cheaper than valuation cost and some others who are selling out of impatience or wanting to realize their gains and you have what we see here - a 30% valuation drop that won‘t be recovered for a while most likely. The future isn‘t all bleak. Of course not. The product has potential and new topline results etc. (if positive) will send this flying back up. Until then, we just have to hold on for the ride. There‘s no regulatory or financial reason for this to go „tits up“ right now, so no reason to panic. Where the evaluation ends up is purely speculative however.·20.2.Here was someone who doesn't think like me, so now I got curious! Let's eat the elephants one bite at a time. In my head, it won't be long until Cereno is a phase 2a company, with an approved study for phase 2b, CRO ready, money ready, I would say that only the planned start in q2 remains. What do you think might additionally remain before you would call them a phase 2b company? Where did you get the market value figure from? Who do you use for comparison? What factors do you base a 500mSEK valuation on? Let's take Edison's analysis as a starting point, which estimates that the company is currently worth 21kr. Now, I'm not saying I think this is correct, and I'm very interested in discussing this to understand better, but for the sake of hypothesis, let's say they have completely missed the mark on most points.(which I don't believe) Even if you remove 2/3 of their estimated value, we are still around the share price we see today. I can agree that there is a risk in the current financing, but everything I have seen from the management so far indicates that this is an extremely competent group who know what they are doing. With the lock up that has been done and the very creative financing, I assume they have some aces up their sleeve towards the summer. What do you think is the root of the financial situation? Also curious about the third elephant… but let's take that when we have gotten through these two. Anyway, cool that you come with other views, as long as we can have a good debate, the worst that can happen is that we learn something from each other.
·21.2. · MuokattuThe problem as I see it is that fas2a was not as good in terms of effect as one had hoped. I believe management expected to enter into some form of partnership or even an exit on fas2a. At the same time, the valuation was pumped up to, as I see it, fantasy sums. No agreements and one must manage the larger economy themselves. But among other things, large loans. Strangely enough, the valuation remains and is defended by everyone who pumped it up on the basis that fas2a would attract BP. Now, as I see it, it will be many years until one gets real effect results that could attract a Pharma. An educated guess is towards 2030. And we do not know the result. As I see it, the risk is greater than the reward at the current valuation. Bv of 0,5mdr feels more reasonable. I have never seen any fas2a company with this high valuation. Everyone, of course, does their own analysis.
·16.2.It seems from the posts that some of you are trying to push the price down by being negative. Fortunately, it doesn't affect most of us who are long-term investors. Have been involved for many years and have great faith that the upturns are not over💪👍·17.2.You exaggerate the importance - and the reason - for more balanced perspectives on Cereno. I don't think anyone is trying to push down the price, rather to provide a counterweight to the uncritical comments. I have been with Cereno since 2023 based on the research. Still believe in the research but think the management is too passive. Received a lot of pushback when I predicted a price decline in October for the coming quarter due to lack of activity (deal). Now we are here.
·16.2. · MuokattuThe support at 6.30 does not seem to hold, and I am very worried about the price development right now. You should be prepared that the probability is increasing that we may soon see levels around 5 kr, which I have mentioned earlier. It is also not impossible that the price may approach 4 kr shortly.·17.2.No one has said that there is no factual information. Where have I written that? What I am pointing out is something completely different: the atmosphere. When the discussion is solely about positive speculations, potential partnerships and “soon-it-will-happen” scenarios, then it's okay. But as soon as someone raises risks, missed results or questions timelines, then warnings and blockings appear. It is that double standard I criticize. Throughout last year, the narrative has revolved around an upcoming deal, a big partnership, a breakthrough around the corner. None of that has happened. It is not “hate” to state that – it is a fact. When hopes are consistently presented as an imminent reality without being delivered, it affects credibility. And when the head administrator in Discord connected to Cereno Scientific also has a history of insider-related issues, then it is reasonable to ask questions about judgment and transparency. It's not about me – it's about trust. A serious forum can handle both optimism and critical scrutiny. If only one side is tolerated, it's not a discussion – it's an echo chamber, but perhaps you don't know what an echo chamber is....
·17.2. · MuokattuOkay 1. I, including several others, hoped for a deal during the autumn. It didn't happen for various reasons. This meant that those who are after quick cash have started to leave the boat. Everyone does as they please. I think that we long-term investors who remain have every right to believe that a deal will come soon. "Soon" is quite a relative concept depending on who you ask. 2. No individual is above the company and the company's research. 3. It's a shame if you were blocked or similar. What I can say from my experience in Discord is that some individuals have asked critical questions, which is great. The problem is that when they get a thorough answer, they continue with mudslinging. I'm not saying it's you, but I don't think people were kicked out because they don't agree with what most people do. I think we close this discussion here and now. I wish you good luck with your investments.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
90 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenWhat do you primarily want to see in the report?2 päivää sitten2 päivää sittenI don't expect anything that wasn't already said at KMD. CU/EAP is the next possible trigger.
- ·20.2.Take the opportunity to invest more now before the report·20.2.Super positive on Cereno, but don't think the report will make any big difference. Have more faith in EAP/CU data towards the end of the quarter.·2 päivää sittenI would rather argue that it is strategically wise not to draw focus away from the clinical results by mixing in a financial report where the only thing we know for sure is that the company is losing money... Even if it is completely according to plan... What needed to be said about the financial aspects was said at the Capital Markets Day, I see this report as a non-event. But that's just me... :P
- 16.2.16.2.Just a sad look for Cereno right now. The people spouting utter nonsense about the 10SEK valuation being justified and holding should be ashamed. It was always going to happen - small cap biotech just happens to live off of hype and news. When there is none and progress is slow, volume dies down and so does appreciation. Insert a couple of big players with exercisable warrants at cheaper than valuation cost and some others who are selling out of impatience or wanting to realize their gains and you have what we see here - a 30% valuation drop that won‘t be recovered for a while most likely. The future isn‘t all bleak. Of course not. The product has potential and new topline results etc. (if positive) will send this flying back up. Until then, we just have to hold on for the ride. There‘s no regulatory or financial reason for this to go „tits up“ right now, so no reason to panic. Where the evaluation ends up is purely speculative however.·20.2.Here was someone who doesn't think like me, so now I got curious! Let's eat the elephants one bite at a time. In my head, it won't be long until Cereno is a phase 2a company, with an approved study for phase 2b, CRO ready, money ready, I would say that only the planned start in q2 remains. What do you think might additionally remain before you would call them a phase 2b company? Where did you get the market value figure from? Who do you use for comparison? What factors do you base a 500mSEK valuation on? Let's take Edison's analysis as a starting point, which estimates that the company is currently worth 21kr. Now, I'm not saying I think this is correct, and I'm very interested in discussing this to understand better, but for the sake of hypothesis, let's say they have completely missed the mark on most points.(which I don't believe) Even if you remove 2/3 of their estimated value, we are still around the share price we see today. I can agree that there is a risk in the current financing, but everything I have seen from the management so far indicates that this is an extremely competent group who know what they are doing. With the lock up that has been done and the very creative financing, I assume they have some aces up their sleeve towards the summer. What do you think is the root of the financial situation? Also curious about the third elephant… but let's take that when we have gotten through these two. Anyway, cool that you come with other views, as long as we can have a good debate, the worst that can happen is that we learn something from each other.·21.2. · MuokattuThe problem as I see it is that fas2a was not as good in terms of effect as one had hoped. I believe management expected to enter into some form of partnership or even an exit on fas2a. At the same time, the valuation was pumped up to, as I see it, fantasy sums. No agreements and one must manage the larger economy themselves. But among other things, large loans. Strangely enough, the valuation remains and is defended by everyone who pumped it up on the basis that fas2a would attract BP. Now, as I see it, it will be many years until one gets real effect results that could attract a Pharma. An educated guess is towards 2030. And we do not know the result. As I see it, the risk is greater than the reward at the current valuation. Bv of 0,5mdr feels more reasonable. I have never seen any fas2a company with this high valuation. Everyone, of course, does their own analysis.
- ·16.2.It seems from the posts that some of you are trying to push the price down by being negative. Fortunately, it doesn't affect most of us who are long-term investors. Have been involved for many years and have great faith that the upturns are not over💪👍·17.2.You exaggerate the importance - and the reason - for more balanced perspectives on Cereno. I don't think anyone is trying to push down the price, rather to provide a counterweight to the uncritical comments. I have been with Cereno since 2023 based on the research. Still believe in the research but think the management is too passive. Received a lot of pushback when I predicted a price decline in October for the coming quarter due to lack of activity (deal). Now we are here.
- ·16.2. · MuokattuThe support at 6.30 does not seem to hold, and I am very worried about the price development right now. You should be prepared that the probability is increasing that we may soon see levels around 5 kr, which I have mentioned earlier. It is also not impossible that the price may approach 4 kr shortly.·17.2.No one has said that there is no factual information. Where have I written that? What I am pointing out is something completely different: the atmosphere. When the discussion is solely about positive speculations, potential partnerships and “soon-it-will-happen” scenarios, then it's okay. But as soon as someone raises risks, missed results or questions timelines, then warnings and blockings appear. It is that double standard I criticize. Throughout last year, the narrative has revolved around an upcoming deal, a big partnership, a breakthrough around the corner. None of that has happened. It is not “hate” to state that – it is a fact. When hopes are consistently presented as an imminent reality without being delivered, it affects credibility. And when the head administrator in Discord connected to Cereno Scientific also has a history of insider-related issues, then it is reasonable to ask questions about judgment and transparency. It's not about me – it's about trust. A serious forum can handle both optimism and critical scrutiny. If only one side is tolerated, it's not a discussion – it's an echo chamber, but perhaps you don't know what an echo chamber is....·17.2. · MuokattuOkay 1. I, including several others, hoped for a deal during the autumn. It didn't happen for various reasons. This meant that those who are after quick cash have started to leave the boat. Everyone does as they please. I think that we long-term investors who remain have every right to believe that a deal will come soon. "Soon" is quite a relative concept depending on who you ask. 2. No individual is above the company and the company's research. 3. It's a shame if you were blocked or similar. What I can say from my experience in Discord is that some individuals have asked critical questions, which is great. The problem is that when they get a thorough answer, they continue with mudslinging. I'm not saying it's you, but I don't think people were kicked out because they don't agree with what most people do. I think we close this discussion here and now. I wish you good luck with your investments.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
2 892
Myynti
Määrä
8 454
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 343 | - | - | ||
| 766 | - | - | ||
| 27 | - | - | ||
| 30 | - | - | ||
| 460 | - | - |
Ylin
6,64VWAP
Alin
6,42VaihtoMäärä
2,4 372 014
VWAP
Ylin
6,64Alin
6,42VaihtoMäärä
2,4 372 014
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 373 021 | 373 021 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 373 021 | 373 021 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 27.2. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 21.11.2024 |
2025 Q3 -tulosraportti
Vain PDF
90 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 27.2. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 21.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenWhat do you primarily want to see in the report?2 päivää sitten2 päivää sittenI don't expect anything that wasn't already said at KMD. CU/EAP is the next possible trigger.
- ·20.2.Take the opportunity to invest more now before the report·20.2.Super positive on Cereno, but don't think the report will make any big difference. Have more faith in EAP/CU data towards the end of the quarter.·2 päivää sittenI would rather argue that it is strategically wise not to draw focus away from the clinical results by mixing in a financial report where the only thing we know for sure is that the company is losing money... Even if it is completely according to plan... What needed to be said about the financial aspects was said at the Capital Markets Day, I see this report as a non-event. But that's just me... :P
- 16.2.16.2.Just a sad look for Cereno right now. The people spouting utter nonsense about the 10SEK valuation being justified and holding should be ashamed. It was always going to happen - small cap biotech just happens to live off of hype and news. When there is none and progress is slow, volume dies down and so does appreciation. Insert a couple of big players with exercisable warrants at cheaper than valuation cost and some others who are selling out of impatience or wanting to realize their gains and you have what we see here - a 30% valuation drop that won‘t be recovered for a while most likely. The future isn‘t all bleak. Of course not. The product has potential and new topline results etc. (if positive) will send this flying back up. Until then, we just have to hold on for the ride. There‘s no regulatory or financial reason for this to go „tits up“ right now, so no reason to panic. Where the evaluation ends up is purely speculative however.·20.2.Here was someone who doesn't think like me, so now I got curious! Let's eat the elephants one bite at a time. In my head, it won't be long until Cereno is a phase 2a company, with an approved study for phase 2b, CRO ready, money ready, I would say that only the planned start in q2 remains. What do you think might additionally remain before you would call them a phase 2b company? Where did you get the market value figure from? Who do you use for comparison? What factors do you base a 500mSEK valuation on? Let's take Edison's analysis as a starting point, which estimates that the company is currently worth 21kr. Now, I'm not saying I think this is correct, and I'm very interested in discussing this to understand better, but for the sake of hypothesis, let's say they have completely missed the mark on most points.(which I don't believe) Even if you remove 2/3 of their estimated value, we are still around the share price we see today. I can agree that there is a risk in the current financing, but everything I have seen from the management so far indicates that this is an extremely competent group who know what they are doing. With the lock up that has been done and the very creative financing, I assume they have some aces up their sleeve towards the summer. What do you think is the root of the financial situation? Also curious about the third elephant… but let's take that when we have gotten through these two. Anyway, cool that you come with other views, as long as we can have a good debate, the worst that can happen is that we learn something from each other.·21.2. · MuokattuThe problem as I see it is that fas2a was not as good in terms of effect as one had hoped. I believe management expected to enter into some form of partnership or even an exit on fas2a. At the same time, the valuation was pumped up to, as I see it, fantasy sums. No agreements and one must manage the larger economy themselves. But among other things, large loans. Strangely enough, the valuation remains and is defended by everyone who pumped it up on the basis that fas2a would attract BP. Now, as I see it, it will be many years until one gets real effect results that could attract a Pharma. An educated guess is towards 2030. And we do not know the result. As I see it, the risk is greater than the reward at the current valuation. Bv of 0,5mdr feels more reasonable. I have never seen any fas2a company with this high valuation. Everyone, of course, does their own analysis.
- ·16.2.It seems from the posts that some of you are trying to push the price down by being negative. Fortunately, it doesn't affect most of us who are long-term investors. Have been involved for many years and have great faith that the upturns are not over💪👍·17.2.You exaggerate the importance - and the reason - for more balanced perspectives on Cereno. I don't think anyone is trying to push down the price, rather to provide a counterweight to the uncritical comments. I have been with Cereno since 2023 based on the research. Still believe in the research but think the management is too passive. Received a lot of pushback when I predicted a price decline in October for the coming quarter due to lack of activity (deal). Now we are here.
- ·16.2. · MuokattuThe support at 6.30 does not seem to hold, and I am very worried about the price development right now. You should be prepared that the probability is increasing that we may soon see levels around 5 kr, which I have mentioned earlier. It is also not impossible that the price may approach 4 kr shortly.·17.2.No one has said that there is no factual information. Where have I written that? What I am pointing out is something completely different: the atmosphere. When the discussion is solely about positive speculations, potential partnerships and “soon-it-will-happen” scenarios, then it's okay. But as soon as someone raises risks, missed results or questions timelines, then warnings and blockings appear. It is that double standard I criticize. Throughout last year, the narrative has revolved around an upcoming deal, a big partnership, a breakthrough around the corner. None of that has happened. It is not “hate” to state that – it is a fact. When hopes are consistently presented as an imminent reality without being delivered, it affects credibility. And when the head administrator in Discord connected to Cereno Scientific also has a history of insider-related issues, then it is reasonable to ask questions about judgment and transparency. It's not about me – it's about trust. A serious forum can handle both optimism and critical scrutiny. If only one side is tolerated, it's not a discussion – it's an echo chamber, but perhaps you don't know what an echo chamber is....·17.2. · MuokattuOkay 1. I, including several others, hoped for a deal during the autumn. It didn't happen for various reasons. This meant that those who are after quick cash have started to leave the boat. Everyone does as they please. I think that we long-term investors who remain have every right to believe that a deal will come soon. "Soon" is quite a relative concept depending on who you ask. 2. No individual is above the company and the company's research. 3. It's a shame if you were blocked or similar. What I can say from my experience in Discord is that some individuals have asked critical questions, which is great. The problem is that when they get a thorough answer, they continue with mudslinging. I'm not saying it's you, but I don't think people were kicked out because they don't agree with what most people do. I think we close this discussion here and now. I wish you good luck with your investments.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
2 892
Myynti
Määrä
8 454
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 343 | - | - | ||
| 766 | - | - | ||
| 27 | - | - | ||
| 30 | - | - | ||
| 460 | - | - |
Ylin
6,64VWAP
Alin
6,42VaihtoMäärä
2,4 372 014
VWAP
Ylin
6,64Alin
6,42VaihtoMäärä
2,4 372 014
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 373 021 | 373 021 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 373 021 | 373 021 | 0 | 0 |